What Cifran ST Treats: Main Uses and Benefits

Cifran ST combines two agents to provide targeted therapeutic support for infections where multiple types of susceptible pathogens are involved, focusing on the symptomatic relief of distressing manifestations. The combination is commonly used in situations involving certain distressing symptoms caused by a diverse range of susceptible bacteria and protozoa. This comprehensive coverage is applied across therapeutic domains where additional symptomatic support is needed in contexts involving mixed microbial causes.

The medication is considered relevant for managing symptoms associated with conditions such as severe infectious diarrhea, dysentery, amebiasis, complicated urinary tract infections (UTIs), chronic bacterial prostatitis, and certain skin and soft tissue infections. It is applied across therapeutic domains involving heightened symptomatic discomfort.

“It assists with maintaining functional stability during phases when symptoms become more noticeable.”

This supportive relief helps improve day-to-day comfort during symptomatic periods by addressing symptoms related to physical discomfort, systemic imbalance, and inflammatory states.

---

Quick Fact: Symptomatic Support for Abdominal Discomfort

Cifran ST is commonly used across conditions presenting with acute episodes of gastrointestinal distress, and may assist with managing symptoms related to a high microbial load.

---

Regulatory References

1. U.S. National Library of Medicine (NIH) on Ciprofloxacin and Tinidazole

The use of Цифран СТ is strictly defined by the regulatory profile of its two active ingredients, Ciprofloxacin and Tinidazole. This medication is primarily established for use in adults (typically aged 18 years and older).

---

Contraindications (Must Not Use)

Population/Condition	Restriction
Hypersensitivity	Known allergy to Ciprofloxacin, Tinidazole, quinolones, or nitroimidazoles.
Myasthenia Gravis	Known history of this muscle weakness condition.
Blood Dyscrasia	History of blood disorders.
Drug-Drug	Concomitant use with Tizanidine.
Pregnancy/Lactation	First Trimester of Pregnancy and Nursing Mothers.

---

Restricted or Conditional Use

Use is generally not recommended in children and growing teenagers due to potential risks, although Ciprofloxacin has specific, limited pediatric indications. Elderly patients must be treated with caution due to an increased risk of tendon problems. Patients with renal impairment (kidney disease) or certain CNS disorders (e.g., history of seizures) require caution and, in the case of renal impairment, a mandated dose adjustment.

Interactions with other medicines and products

Official regulatory information for Цифран СТ (Ciprofloxacin and Tinidazole) outlines specific combinations and requirements that must be followed during use. These constraints are primarily based on altering drug clearance, potential systemic potentiation, and reduced absorption, as documented by national medicines authorities.

Contraindicated Combination

The co-administration of Ciprofloxacin with Tizanidine is strictly prohibited due to the potential for severe potentiation of hypotensive and sedative effects.

Officially Documented Interactions and Constraints

Interaction Type	Interacting Agent (Examples)	Official Constraint or Outcome
Metabolic Inhibition	Theophylline, Caffeine	Ciprofloxacin decreases clearance, leading to elevated plasma levels.
Pharmacodynamic Potentiation	Warfarin, Oral Antidiabetic Agents	Enhanced anticoagulant effect (bleeding risk) or potentiated glucose-lowering effect (hypoglycemia risk).
Absorption Interference	Antacids (Aluminum/Magnesium), Iron, Zinc	Absorption of Ciprofloxacin is significantly reduced.

Procedural and Timing Requirements

Multivalent cation-containing products must be administered at least 2 hours before or 6 hours after Ciprofloxacin to ensure proper drug absorption. Separately, the ingestion of alcohol-containing products must be avoided during Tinidazole therapy and for a minimum of three days following its discontinuation due to the risk of a disulfiram-like reaction.

How Цифран СТ Works

Цифран СТ operates through two distinct molecular mechanisms targeting the essential genetic machinery of different pathogen types.

---

Targeted Inhibition of Aerobic DNA Replication

This domain covers the action of Ciprofloxacin, which acts as an inhibitor of the core bacterial enzymes DNA Gyrase (Topoisomerase II) and Topoisomerase IV. By trapping these enzymes, Ciprofloxacin induces lethal double-stranded DNA breaks in susceptible aerobic bacteria, resulting in the rapid cessation of replication and transcription, which triggers rapid, mechanism-dependent microbial cell death.

---

️ Reduction-Dependent Destruction of Anaerobic DNA

This domain involves Tinidazole, a pro-drug whose mechanism is activated exclusively by microbial nitroreductase enzymes in low-oxygen (anaerobic) environments. This bioactivation generates cytotoxic free radicals that directly attack and fragment the DNA of anaerobic bacteria and protozoa, causing irreversible structural damage and resulting in the molecular-level destruction and subsequent clearance of these specific microbes.

---

Synergistic Dual-Mechanism Pathogen Coverage

The combination utilizes these two specialized mechanisms. The synergy means one component targets susceptible aerobic organisms (via enzyme inhibition) while the other acts to eliminate susceptible anaerobic/protozoal cells (via DNA destruction), providing broad molecular coverage through two distinct mechanisms that lead to cell death.

How to Use Цифран СТ

The administration of Цифран СТ follows specific parameters to ensure appropriate exposure to the combination of ciprofloxacin and tinidazole. This information focuses on the route, dosage, timing, and population-specific considerations.

The combination product is designated exclusively for oral use in the form of a film-coated tablet. The standard adult dosing regimen involves taking one tablet twice daily (every 12 hours) over a finite course of therapy, which typically ranges from five to ten days for acute conditions. The tablet must be swallowed whole with water and should not be crushed, split, or chewed.

A critical instruction related to absorption involves timing the dose relative to products containing multivalent cations (e.g., calcium, iron, zinc). The medication must be taken at least two to six hours apart from these mineral-containing substances, including certain antacids and dairy products, to maintain effective drug levels. Furthermore, dose adjustments for the ciprofloxacin component are required in adult patients with impaired kidney function. If a dose is missed, the standard approach is to take it as soon as remembered, unless it is near the time for the next scheduled dose, in which case the missed dose should be skipped.

Standard Administration Summary

Instruction Domain	Guideline
Route	Oral use only.
Standard Adult Dose	One tablet twice daily (q12h).
Duration	Short-term, defined course (e.g., 5 to 10 days).
Timing Constraint	Must be separated by 2–6 hours from multivalent cations.
Special Rule	Dose adjustment required in renal impairment.

Research Evidence Overview for Цифран СТ (Ciprofloxacin and Tinidazole)

---

Evidence for Use in Mixed Bacterial and Protozoal Infections

Research has examined the use of the combination of ciprofloxacin and tinidazole in clinical trials involving adult populations with various infections suspected to be caused by both bacterial and protozoal pathogens. These studies monitored outcomes related to outcomes related to physical discomfort and measured the clearance of targeted microorganisms from the body. Studies reported measurements related to the presence or absence of the specific pathogens being tracked. Long-term effects are not fully established for this indication, as follow-up durations were limited in many studies, and the evidence quality varies across studies due to patient heterogeneity.

---

Evidence for Use in Skin and Soft Tissue Infections (SSTI)

This drug combination was evaluated in clinical trials focusing on adults with certain types of skin and soft tissue infections, including those in high-risk or surgical settings. Research examined outcomes such as change in wound healing metrics and microbiological findings. The studies monitored clinical measurements and described patterns of symptom evolution over the short treatment course. Data for certain groups remain insufficient, particularly for patients with less complex infections, and the generalizability of the findings may be limited due to the focus on complex subgroups.

---

Evidence in Special Patient Populations and Uncertainties

Research for the combination was evaluated in trials primarily enrolling a general adult population. Data for certain groups remain insufficient or non-existent, including comparative evidence for children and adolescents. While research has explored the use of the combination in older adults, the subgroup findings are uncertain due to limited patient numbers in specific analyses. Overall, the follow-up durations were limited across many relevant studies, leaving long-term outcomes not fully established. Findings describe group patterns, not personal outcomes.

Key Studies & References

1. Efficacy and safety of ciprofloxacin plus tinidazole in the treatment of intra-abdominal and mixed infections: a comparative study
2. Tinidazole: a review of its use in the treatment of protozoal infections

Common questions about Цифран СТ (FAQ)

Q: Does this medicine have any application in treating infections caused by viruses, such as a cold or flu?

Official product information describes this medicine as a combination of antibacterial and antiprotozoal agents. Its use is therefore limited to treating infections that are proven or strongly suspected to be caused by susceptible bacteria or protozoa. Regulatory documents indicate that the medicine is not intended for the treatment of infections caused by viruses, such as a cold or flu.

Q: What is the information regarding the drug's potential effect on heart rhythm (e.g., QT prolongation)?

The ciprofloxacin component has been associated in regulatory warnings with the prolongation of the QT interval on the electrocardiogram. This is a measurement of the heart's electrical rhythm. Official sources describe that the drug carries a warning regarding its use in patients who already have known QT prolongation or uncorrected hypokalemia (low potassium).

Q: Is an increase in sensitivity to sunlight a known side effect of the Ciprofloxacin component?

Yes, the ciprofloxacin component of this medicine has been associated with photosensitivity or phototoxicity reactions in regulatory labeling. This is a documented side effect that may cause an exaggerated sunburn reaction. Official guidance notes that avoiding excessive exposure to sunlight or ultraviolet light is advised while using this medicine.

Q: Are there specific over-the-counter pain relievers or NSAIDs that should be avoided with Цифран СТ?

Official documents mention that certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may interact with the ciprofloxacin component. This includes common over-the-counter pain relievers such as ibuprofen or naproxen.

Q: Is there any effect on the effectiveness of hormonal contraceptives when taking Цифран СТ?

Regulatory information indicates that antibiotics within this class may reduce the effectiveness of some hormonal contraceptives. This creates a potential risk for the patient. This potential interaction is generally listed as a topic for discussion with a healthcare professional.

Q: Does having a connective tissue disorder affect eligibility for Цифран СТ?

This class of medicine carries an explicit warning in regulatory documents regarding the risk of Aortic Aneurysm and Dissection. This condition involves the main artery of the body and is a safety concern related to the integrity of the body's major blood vessels.

Q: Is it common to feel a difference in energy levels during the course of treatment?

While low energy or fatigue is not explicitly listed as a common effect, regulatory warnings do document adverse Central Nervous System (CNS) effects. These can include symptoms such as confusion, anxiety, and insomnia, which may indirectly affect a person's perceived energy levels.

Q: Does the treatment need to be completed even if symptoms appear to be gone? (General principle)

Regulatory documents emphasize that use is intended to reduce the risk of developing drug-resistant bacteria. Finishing the full course, even after symptoms improve, is the widely referenced principle related to achieving clearance of the targeted infection and minimizing the potential for resistance.

Q: Why is adequate hydration recommended when taking this specific antibiotic component?

Official product information describes that patients taking this medicine should maintain adequate hydration. This precaution is taken because ciprofloxacin crystals (crystalluria) have been observed in urine, and being well hydrated may help prevent the formation of highly concentrated urine.

Q: What is the meaning of "photosensitivity" as it relates to Цифран СТ?

In the context of this medicine's warnings, photosensitivity refers to a potential adverse effect that may manifest as an exaggerated sunburn reaction. This involves burning, redness, or blistering when areas of the skin are exposed to sunlight or UV light.

Q: What is the general research theme regarding antibiotic-associated colitis and this drug?

Safety warnings regarding this drug include the risk of Clostridioides difficile-associated diarrhea (CDAD). Official documents report that this condition has been observed with the use of antibacterial agents, including ciprofloxacin, and may range in severity from mild diarrhea to fatal colitis.

Q: Why is it recommended to be cautious about taking this medicine if one has an irregular heartbeat?

Caution is advised because the ciprofloxacin component is associated with prolongation of the QT interval on the electrocardiogram. In infrequent cases, this electrical change can lead to an irregular heartbeat, or arrhythmia, which is why caution is listed in regulatory information.

Official Storage and Disposal Requirements

Storage of Cifran CT (Цифран СТ) is strictly defined by regulatory guidelines to ensure product stability and safety. The medicine must be stored at a controlled temperature not exceeding 25°C and must not be frozen. It is mandatory to keep the tablets in a dry place and protected from light.

Requirement	Official Rule
Temperature	Do not exceed 25 C / Do not freeze
Protection	Keep dry and protected from light
Shelf Life	2 years (Do not use after expiry)
Safety	Keep out of the reach of children

The official shelf life is two years; the product must not be used past this expiry date. For disposal, unused or expired medication should be returned to a pharmacist for appropriate pharmaceutical waste handling, as documented in regulatory sources.